Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Bacterial Composition Linked to Breast Cancer

By LabMedica International staff writers
Posted on 19 Oct 2017
Breast cancer is the second most common cancer in women (after skin cancer) in the USA, where one in eight women will develop the disease in their lifetimes. Bacteria that live in the body is known as the microbiome, and influence many diseases.

Most studies have been done on the "gut" microbiome, or bacteria in the digestive tract. Scientists have long suspected that a "microbiome" exists within breast tissue and plays a role in breast cancer, but it has not yet been characterized. Recently they have uncovered differences in the bacterial composition of breast tissue of healthy women versus women with breast cancer.

Scientists at the Cleveland Clinic (Cleveland, OH, USA) examined the tissues of 78 patients who underwent mastectomy for invasive carcinoma or elective cosmetic breast surgery. In addition, they examined oral rinse and urine to determine the bacterial composition of these distant sites in the body. Breast cancer patients eligible for inclusion for this study were over 18 years of age, female, had tumors greater than or equal to 2 cm in size, and were undergoing mastectomy.

The team extracted total DNA was from the breast tissue, environmental controls, urine, and oral rinse pellets using PowerMag Microbiome RNA/DNA Isolation Kit. For breast samples, the polymerase chain reaction (PCR) product showed nonspecific bands on a 1% agarose gel. A second round of Ampure XP cleanup was performed and resulting libraries were quantified with Quantiflour dsDNA system. Libraries were validated on a Bioanalyzer DNA 1000 chip to verify size and sequenced.

The scientists found that cancer patient breast tissue microbiomes clustered significantly differently from non-cancer patients, largely driven by decreased relative abundance of Methylobacterium in cancer patients (median 0.10 versus 0.24). There were no significant differences in oral rinse samples. Differences in urinary microbiomes were largely explained by menopausal status, with peri/postmenopausal women showing decreased levels of Lactobacillus. Independent of menopausal status, however, cancer patients had increased levels of gram-positive organisms including Corynebacterium, Staphylococcus, Actinomyces, and Propionibacteriaceae.

Charis Eng, MD, PhD, the co-senior author of the study, said, “To my knowledge, this is the first study to examine both breast tissue and distant sites of the body for bacterial differences in breast cancer. Our hope is to find a biomarker that would help us diagnose breast cancer quickly and easily. In our wildest dreams, we hope we can use microbiomics right before breast cancer forms and then prevent cancer with probiotics or antibiotics.” The study was published on October 5, 2017, in the journal Oncotarget.

Related Links:
Cleveland Clinic


Gold Member
Pharmacogenetics Panel
VeriDose Core Panel v2.0
Verification Panels for Assay Development & QC
Seroconversion Panels
New
H.pylori Test
Humasis H.pylori Card
New
Coagulation Analyzer
CS-2400
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get complete access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Immunology

view channel
Image: The findings were based on patients from the ADAURA clinical trial of the targeted therapy osimertinib for patients with NSCLC with EGFR-activated mutations (Photo courtesy of YSM Multimedia Team)

Post-Treatment Blood Test Could Inform Future Cancer Therapy Decisions

In the ongoing advancement of personalized medicine, a new study has provided evidence supporting the use of a tool that detects cancer-derived molecules in the blood of lung cancer patients years after... Read more

Microbiology

view channel
Image: Schematic representation illustrating the key findings of the study (Photo courtesy of UNIST)

Breakthrough Diagnostic Technology Identifies Bacterial Infections with Almost 100% Accuracy within Three Hours

Rapid and precise identification of pathogenic microbes in patient samples is essential for the effective treatment of acute infectious diseases, such as sepsis. The fluorescence in situ hybridization... Read more

Industry

view channel
Image: Tumor-associated macrophages visualized using the Multiomic LS Assay (Photo courtesy of ACD)

Leica Biosystems and Bio-Techne Expand Spatial Multiomic Collaboration

Bio-Techne Corporation (Minneapolis, MN, USA) has expanded the longstanding partnership between its spatial biology brand, Advanced Cell Diagnostics (ACD, Newark, CA, USA), and Leica Biosystems (Nussloch,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.